$0.17 EPS Expected for Retrophin, Inc. (RTRX) This Quarter

Equities research analysts expect that Retrophin, Inc. (NASDAQ:RTRX) will post $0.17 earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Retrophin’s earnings, with estimates ranging from $0.11 to $0.22. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 7th.

On average, analysts expect that Retrophin will report full year earnings of $0.39 per share for the current fiscal year, with EPS estimates ranging from $0.37 to $0.41. For the next year, analysts expect that the firm will post earnings of $0.47 per share, with EPS estimates ranging from $0.26 to $0.68. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Retrophin.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.21). The company had revenue of $40.34 million for the quarter, compared to analyst estimates of $40.51 million. Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.09) earnings per share.

A number of brokerages recently issued reports on RTRX. Zacks Investment Research downgraded Retrophin from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 14th. BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 price target on shares of Retrophin in a report on Friday, October 6th. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Finally, BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Two equities research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $36.00.

Several hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC boosted its holdings in shares of Retrophin by 0.5% in the third quarter. Perceptive Advisors LLC now owns 2,686,204 shares of the biopharmaceutical company’s stock valued at $66,859,000 after acquiring an additional 13,895 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Retrophin by 8.3% in the second quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock valued at $31,707,000 after acquiring an additional 125,695 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Retrophin by 22.7% in the third quarter. Macquarie Group Ltd. now owns 1,459,218 shares of the biopharmaceutical company’s stock valued at $36,320,000 after acquiring an additional 270,399 shares during the period. Oak Ridge Investments LLC raised its stake in shares of Retrophin by 96.9% during the second quarter. Oak Ridge Investments LLC now owns 1,022,871 shares of the biopharmaceutical company’s stock worth $19,833,000 after purchasing an additional 503,428 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Retrophin by 8.7% during the third quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock worth $22,322,000 after purchasing an additional 71,562 shares during the last quarter.

Shares of Retrophin (NASDAQ:RTRX) traded down $0.74 on Monday, reaching $21.80. The company had a trading volume of 222,400 shares, compared to its average volume of 328,370. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.88 and a quick ratio of 3.83. Retrophin has a 52-week low of $15.55 and a 52-week high of $26.44.

TRADEMARK VIOLATION NOTICE: This article was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/04/0-17-eps-expected-for-retrophin-inc-rtrx-this-quarter.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

What are top analysts saying about Retrophin Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Retrophin Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit